News Center
Stay updated with GRIT Bio's latest developments and cutting-edge advances in cell therapy
11/5/2026
Three Grit Bio Posters Accepted at SITC 2026: New Data on Neoantigen mRNA Vaccine and In Vivo CAR-T Platforms
Read More
News
10/30/2026
Grit Bio’s GT101 Receives U.S. IND Clearance to Advance First-Line HNSCC Clinical Development in China and the U.S.
Read More
10/19/2026
Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia
Read More
News
9/23/2026
Next-Generation TIL | Dr. Yin Cheng Speaks at Lonza × CSGCT CGT Innovation Technology Forum
Read More
News
9/21/2026
Breaking News | Grit Bio and Vivacta Bio Honored as “Innovative Pioneer Enterprises” at 2026 CSGCT
Read More
News
8/21/2026
Moderna Shares Surge 160% as Its Neoantigen Vaccine Advances Through Phase 3: How GRIT Bio Stands Out
Read More
News
7/24/2026
GRIT Bio and Drug Farm Partner to Co-Develop KunEvo, an AI-Native Platform for Translational Research and Drug Development
Read More
News
7/24/2026
GRIT Bio Opens Beijing Headquarters to Advance Next-Generation T-Cell Therapies
Read More
News
6/24/2026
GT101 Receives IND Clearance in China for First-Line Head and Neck Squamous Cell Carcinoma—the First TIL Therapy Cleared for This Indication
Read More